Travis M Shaffer1, Amin Aalipour2, Christian M Schürch3, Sanjiv S Gambhir4,2,5. 1. Department of Radiology, Stanford University, Stanford, California. 2. Department of Bioengineering, Stanford University, Stanford, California. 3. Department of Microbiology and Immunology, Stanford University, Stanford, California; and. 4. Department of Radiology, Stanford University, Stanford, California tshaffer@stanford.edu sgambhir@stanford.edu. 5. Bio-X Program and Molecular Imaging Program at Stanford, Stanford University, Stanford, California.
Abstract
Redirecting the immune system in cancer treatment has led to remarkable responses in a subset of patients. Natural killer (NK) cells are innate lymphoid cells being explored as they engage tumor cells in different mechanisms compared with T cells, which could be exploited for treatment of nonresponders to current immunotherapies. NK cell therapies are monitored through measuring peripheral NK cell concentrations or changes in tumor volume over time. The former does not detect NK cells at the tumor site, and the latter is inaccurate for immunotherapies because of pseudoprogression. Therefore, new imaging methods are required as companion diagnostics for optimizing immunotherapies. Methods: In this study, we developed and completed preclinical in vivo validation of 2 antibody-based PET probes specific for NKp30, an activation natural cytotoxicity receptor expressed by human NK cells. Quantitative, multicolor flow cytometry during a variety of NK cell activation conditions was completed on primary human NK cells and the NK92MI cell line. Human renal cell carcinoma (RCC) tumors were stained for the NK cell receptors CD56, NKp30, and NKp46 to determine expression on tumor-infiltrating NK cells. An NKp30 antibody was radiolabeled with 64Cu or 89Zr and evaluated in subcutaneous xenografts and adoptive cell transfer mouse models. Results: Quantitative flow cytometry showed consistent expression of the NKp30 receptor during different activation conditions. NKp30 and NKp46 costained in RCC samples, demonstrating the expression of these receptors on tumor-infiltrating NK cells in human tumors, whereas tumor cells in one RCC sample expressed the peripheral NK marker CD56. Both PET tracers showed high stability and specificity in vitro and in vivo. Notably, 89Zr-NKp30Ab had higher on-target contrast than 64Cu-NKp30Ab at their respective terminal time points. 64Cu-NKp30Ab delineated NK cell trafficking to the liver and spleen in an adoptive cell transfer model. Conclusion: The consistent expression of NKp30 on NK cells makes it an attractive target for quantitative imaging. Immunofluorescence staining on human RCC samples demonstrated the advantages of NKp30 targeting versus CD56 for detection of tumor infiltrating NK cells. This work advances PET imaging of NK cells and supports the translation of imaging agents for immunotherapy monitoring.
Redirecting the immune system in cancer treatment has led to remarkable responses in a subset of patients. Natural killer (NK) cells are innate lymphoid cells being explored as they engage tumor cells in different mechanisms compared with T cells, which could be exploited for treatment of nonresponders to current immunotherapies. NK cell therapies are monitored through measuring peripheral NK cell concentrations or changes in tumor volume over time. The former does not detect NK cells at the tumor site, and the latter is inaccurate for immunotherapies because of pseudoprogression. Therefore, new imaging methods are required as companion diagnostics for optimizing immunotherapies. Methods: In this study, we developed and completed preclinical in vivo validation of 2 antibody-based PET probes specific for NKp30, an activation natural cytotoxicity receptor expressed by human NK cells. Quantitative, multicolor flow cytometry during a variety of NK cell activation conditions was completed on primary human NK cells and the NK92MI cell line. Humanrenal cell carcinoma (RCC) tumors were stained for the NK cell receptors CD56, NKp30, and NKp46 to determine expression on tumor-infiltrating NK cells. An NKp30 antibody was radiolabeled with 64Cu or 89Zr and evaluated in subcutaneous xenografts and adoptive cell transfer mouse models. Results: Quantitative flow cytometry showed consistent expression of the NKp30 receptor during different activation conditions. NKp30 and NKp46 costained in RCC samples, demonstrating the expression of these receptors on tumor-infiltrating NK cells in humantumors, whereas tumor cells in one RCC sample expressed the peripheral NK marker CD56. Both PET tracers showed high stability and specificity in vitro and in vivo. Notably, 89Zr-NKp30Ab had higher on-target contrast than 64Cu-NKp30Ab at their respective terminal time points. 64Cu-NKp30Ab delineated NK cell trafficking to the liver and spleen in an adoptive cell transfer model. Conclusion: The consistent expression of NKp30 on NK cells makes it an attractive target for quantitative imaging. Immunofluorescence staining on humanRCC samples demonstrated the advantages of NKp30 targeting versus CD56 for detection of tumor infiltrating NK cells. This work advances PET imaging of NK cells and supports the translation of imaging agents for immunotherapy monitoring.
Authors: Khun Visith Keu; Timothy H Witney; Shahriar Yaghoubi; Jarrett Rosenberg; Anita Kurien; Rachel Magnusson; John Williams; Frezghi Habte; Jamie R Wagner; Stephen Forman; Christine Brown; Martin Allen-Auerbach; Johannes Czernin; Winson Tang; Michael C Jensen; Behnam Badie; Sanjiv S Gambhir Journal: Sci Transl Med Date: 2017-01-18 Impact factor: 17.956
Authors: Noriko Sato; Haitao Wu; Kingsley O Asiedu; Lawrence P Szajek; Gary L Griffiths; Peter L Choyke Journal: Radiology Date: 2015-02-20 Impact factor: 11.105
Authors: Aura Muntasell; Maria C Ochoa; Luna Cordeiro; Pedro Berraondo; Ascension López-Díaz de Cerio; Mariona Cabo; Miguel López-Botet; Ignacio Melero Journal: Curr Opin Immunol Date: 2017-02-23 Impact factor: 7.486
Authors: Jeannette Cany; Anniek B van der Waart; Marleen Tordoir; Gerben M Franssen; Basav N Hangalapura; Jolanda de Vries; Otto Boerman; Nicolaas Schaap; Robbert van der Voort; Jan Spanholtz; Harry Dolstra Journal: PLoS One Date: 2013-06-05 Impact factor: 3.240
Authors: Omar Abousaway; Taha Rakhshandehroo; Annick D Van den Abbeele; Moritz F Kircher; Mohammad Rashidian Journal: Nanotheranostics Date: 2021-01-01